Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Infliximab (Remicade) Clear all

Conditions: Rheumatoid Arthritis
Interventions: Infliximab; Biological
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 45
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more

Conditions: Crohn's Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: COPD, Pulmonary Disease, Chronic Obstructive
Interventions: Collection of safety data for Cohort 1; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: Not listed
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 26
States / cities: Anaheim, California • San Diego, California • Bay Pines, Florida + 23 more

Conditions: Berylliosis, Beryllium Disease
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Maier, Lisa, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Inflammatory Bowel Disease, Crohn's Disease
Interventions: Small bowel ultrasound; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 6 Years to 23 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease
Interventions: Infliximab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteer
Interventions: MT-201; Drug
Lead sponsor: Mirador Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab; Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 85
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 82 more

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions: Azathioprine, 6 mercaptopurine, Methotrexate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Colitis, Ulcerative
Interventions: Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C; Biological
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more

Conditions: Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions: Infliximab; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 23
States / cities: New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more

Conditions: Crohn Disease
Interventions: Infliximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Years to 20 Years
Enrollment: 107 participants
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Infliximab, Adalimumab, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Ulcerative Colitis
Interventions: A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention; Other · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Relapsing Polychondritis
Interventions: Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab; Drug · Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COVID-19
Interventions: Infliximab; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Multisystem Inflammatory Syndrome-Children
Interventions: Infliximab, Anakinra, Methylprednisolone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Up to 20 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Diego, California • Detroit, Michigan

Conditions: Graft vs Host Disease
Interventions: Infliximab; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Juvenile Rheumatoid Arthritis
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inflammatory Bowel Diseases
Interventions: No Intervention; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 6 Years to 23 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Arthritis, Rheumatoid
Interventions: Inflectra; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Collegeville, Pennsylvania

Search by objective public record fields.

RESTART C0168Z05 Rheumatoid Arthritis Study

Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Beryllium Infliximab Study: Clinical Interventional Trial

The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator

Determination of the Optimal Treatment Target in Ulcerative Colitis

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

Biomarkers to Predict and Monitor Response to Infliximab

Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

MIS-C Comparative Effectiveness Study

GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease

Infliximab to Treat Children With Juvenile Rheumatoid Arthritis

Individualized Infiximab Dosing-Proof of Concept Study

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry